Stage III NSCLC comprises a heterogeneous group of patients. It includes both resectable disease, for which the standard of care is surgery plus (neo) adjuvant chemotherapy/immunotherapy, and unresectable disease, for which the standard of care is concurrent chemoradiotherapy (CCRT) followed by one year of adjuvant durvalumab.
Survival in stage III NSCLC is still poor, despite all the progress made in recent years, with the advent of immunotherapy. Many questions and unmet clinical needs are still to be addressed in both resectable and unresectable disease, in order to further improve patients' survival and limit toxicities. It is unlikely that a “one fits all” model or simply adding new drugs, represent the best solutions. Predictive biomarkers are strongly needed and identifying the patients who benefit the most from a specific treatment would be key. Adaptive strategies to spare unnecessary treatment (e.g. adjuvant therapy for patients cured with surgery alone) or to timely escalate therapy might also be important. With this Research Topic, we aim to shed some light on the best treatment for patients with stage III NSCLC.
We welcome Brief Research Reports, Clinical Trials, Hypothesis & Theory, Original Research, Perspectives, Mini Review, Reviews, and Systematic Reviews focused on, but not limited to:
- potential predictive biomarkers
- special populations (especially the ones not included in clinical trials)
- innovative strategies for improving survival (regarding immunotherapy, radiation therapy, and chemotherapy)
- strategies for reducing toxicities and patients' monitoring;
- insights in tumor biology
Please note: Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Stage III NSCLC comprises a heterogeneous group of patients. It includes both resectable disease, for which the standard of care is surgery plus (neo) adjuvant chemotherapy/immunotherapy, and unresectable disease, for which the standard of care is concurrent chemoradiotherapy (CCRT) followed by one year of adjuvant durvalumab.
Survival in stage III NSCLC is still poor, despite all the progress made in recent years, with the advent of immunotherapy. Many questions and unmet clinical needs are still to be addressed in both resectable and unresectable disease, in order to further improve patients' survival and limit toxicities. It is unlikely that a “one fits all” model or simply adding new drugs, represent the best solutions. Predictive biomarkers are strongly needed and identifying the patients who benefit the most from a specific treatment would be key. Adaptive strategies to spare unnecessary treatment (e.g. adjuvant therapy for patients cured with surgery alone) or to timely escalate therapy might also be important. With this Research Topic, we aim to shed some light on the best treatment for patients with stage III NSCLC.
We welcome Brief Research Reports, Clinical Trials, Hypothesis & Theory, Original Research, Perspectives, Mini Review, Reviews, and Systematic Reviews focused on, but not limited to:
- potential predictive biomarkers
- special populations (especially the ones not included in clinical trials)
- innovative strategies for improving survival (regarding immunotherapy, radiation therapy, and chemotherapy)
- strategies for reducing toxicities and patients' monitoring;
- insights in tumor biology
Please note: Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
